Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections

(2019) Chintan V. Dave et al.   ANNALS OF INTERNAL MEDICINE

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records

(2018) Elisabetta Patorno et al.   DIABETES OBESITY & METABOLISM

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

(2018) Bernhard Ludvik et al.   Lancet Diabetes & Endocrinology

Comparative risk of genital infections associated with SGLT2 inhibitors: A real-world retrospective cohort study

(2018) Chintan V. Dave et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2018) Thomas A Zelniker et al.   LANCET

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor

(2017) Michael Fralick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

(2016) Juan P Frías et al.   Lancet Diabetes & Endocrinology

Meta-analysis of few small studies in orphan diseases

(2016) Tim Friede et al.   Research Synthesis Methods

The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus

(2015) Volker Vallon   Annual Review of Medicine

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

A systematic review of validated methods for identifying heart failure using administrative data

(2012) Jane S. Saczynski et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A combined comorbidity score predicted mortality in elderly patients better than existing scores

(2011) Joshua J. Gagne et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research

(2009) Peter C. Austin   COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION